VarmX B.V. is a privately owned spin-out company of the Leiden University Medical Center in the Netherlands. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients.


The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.


These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.


The chief executive officer of VarmX is Paul Bilars, and Pieter Reitsma acts as chief scientific officer.





VarmX announces publication in Nature Communications of their snake venom inspired approach to restore blood clotting in patients using anticoagulants.


Direct link to the publication in Nature Communications.


JUNE 2017:

VarmX raises seed capital for development of modified blood coagulation factor X



Contact information:

VarmX B.V.

Middelweg 38 B

2312 KJ Leiden

The Netherlands


+31 71 5156127




KvK 65920112